International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol
2011

International Study to Predict Optimized Treatment for Depression (iSPOT-D)

Sample size: 2016 publication 10 minutes Evidence: high

Author Information

Author(s): Leanne M Williams, John A Rush, Stephen H Koslow, Stephen R Wisniewski, Nicholas J Cooper, Charles B Nemeroff, Alan F Schatzberg, Evian Gordon

Primary Institution: BRAINnet Foundation

Hypothesis

The aim of iSPOT-D is to identify pretreatment measures that predict or moderate MDD treatment response or remission to escitalopram, sertraline or venlafaxine.

Conclusion

iSPOT-D aims to identify moderators and predictors of treatment response among three treatments: escitalopram, sertraline, and venlafaxine-XR.

Supporting Evidence

  • Major depressive disorder (MDD) is the fourth most disabling medical condition worldwide.
  • Only about 50% of patients with MDD show a response to antidepressant medications.
  • The study aims to mirror clinical practice in a representative spectrum of outpatients.

Takeaway

This study is trying to find out what factors can help predict how well different depression treatments work for people.

Methodology

The study is a multi-centre, international, randomized, prospective, open-label trial enrolling 2016 MDD outpatients.

Potential Biases

Potential biases may arise from the open-label design and the reliance on self-reported measures.

Limitations

The study excludes patients over age 65 and adolescents/children due to potential interactions with medications.

Participant Demographics

Participants are MDD outpatients aged 18-65, with a mix of genders and educational backgrounds.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1745-6215-12-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication